Bayer HealthCare / News archive

News archive

Topic
Product
Date
2015-07-31
FDA Approves Bayer’s Finacea® (azelaic acid) Foam for the Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea

FDA Approves Bayer’s Finacea® (azelaic acid) Foam for the Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea #

The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea® Foam compared to the foam vehicle (without the drug azelaic acid) in the topical treatment of papulopustular rosacea.   » more

2015-07-29
Bayer significantly improves earnings

Bayer significantly improves earnings

The Bayer Group continued to grow sales in the second quarter of 2015 and significantly increased earnings. “All three subgroups contributed to the gratifying improvement in earnings,” said Bayer CEO Dr. Marijn Dekkers when the interim report was published on Wednesday.   » more

2015-07-28
Bayer HealthCare Enters Into Collaboration With Sprint Bioscience On Tumor Metabolism Program

Bayer HealthCare Enters Into Collaboration With Sprint Bioscience On Tumor Metabolism Program

Bayer HealthCare (Bayer) and the Swedish company Sprint Bioscience AB (Sprint Bioscience) have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates.   » more

2015-07-14
Bayer receives European approval for Gadovist® (gadobutrol) for use in pediatric patients less than 2 years of age

Bayer receives European approval for Gadovist® (gadobutrol) for use in pediatric patients less than 2 years of age #

Bayer HealthCare announced today that Gadovist® (gadobutrol) has received a label extension in the European Union (EU) for diagnostic use with magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA) in pediatric patients less than 2 years of age, including term newborns.   » more

2015-06-30
Bayer Submits an Application for Market Authorization of Recombinant Factor VIII Product as a Treatment of Hemophilia A in Japan

Bayer Submits an Application for Market Authorization of Recombinant Factor VIII Product as a Treatment of Hemophilia A in Japan #

Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application for marketing authorization for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound, as a treatment of hemophilia A.   » more

2015-06-26
Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan

Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan #

Bayer HealthCare has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for EYLEA® (aflibercept solution for injection) for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO).   » more

2015-06-17

Bayer to Present New Data on Copanlisib in Hematological Malignancies #

Copanlisib is Bayer’s most advanced hematological oncology compound and one of Bayer’s key pipeline assets with a broad clinical development program of Phase II and Phase III studies / Phase III trial CHRONOS-2 open for enrollment, Phase III trial CHRONOS-3 expected to open for enrollment in second half of 2015   » more

2015-06-16
Bayer HealthCare and Johns Hopkins University Collaborate to Develop New Ophthalmic Therapies

Bayer HealthCare and Johns Hopkins University Collaborate to Develop New Ophthalmic Therapies

Bayer HealthCare (Bayer) and The Johns Hopkins University in Baltimore, Maryland, U.S., have entered into a five-year collaboration agreement to develop new ophthalmic therapies targeting retinal diseases.   » more

2015-06-15

Bayer to Present Latest Advances in Hemophilia Research at the ISTH 2015 Annual Congress in Toronto #

Bayer HealthCare will be presenting new data on treatments for hemophilia A at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Annual Congress to be held June 20 - 25, in Toronto. More than 20 abstracts have been accepted for presentation, including five oral and 18 poster presentations.   » more

2015-06-15

New Clinical Data Further Supporting the Positive Benefit Risk Profile of Bayer’s Xarelto® and Real Life Insights to be Presented at ISTH 2015 #

Bayer HealthCare announced today that new clinical data on its oral Factor Xa inhibitor Xarelto® (rivaroxaban) along with further real life insights will be presented at the XXVth Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Toronto, Canada, June 20 – 25, 2015 providing physicians with a broader understanding of blood clot management in everyday clinical practice.   » more

2015-06-10
Bayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million

Bayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million

Bayer AG has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation.   » more

2015-05-28
Bayer Extends Clinical Investigation of Xarelto® for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Bayer Extends Clinical Investigation of Xarelto® for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer #

Bayer HealthCare and its development partner Janssen Pharmaceuticals, Inc. announced today the initiation of the CALLISTO Clinical Research Programme to explore the potential benefits of the oral Factor Xa inhibitor Xarelto® (rivaroxaban) for the prevention and treatment of pulmonary embolism and deep vein thrombosis in patients with various types of cancer.   » more

2015-05-27
Bayer has outstanding perspectives as a pure Life Science company

Bayer has outstanding perspectives as a pure Life Science company

The Bayer Group can look back at a year of significant strategic positioning. “2014 wasn’t just a year full of important strategic decisions for us, it was also a very successful year operationally,” said Management Board Chairman Dr. Marijn Dekkers on Wednesday at the Annual Stockholders’ Meeting of Bayer AG in Cologne.   » more

2015-05-13

Bayer to Present Latest Oncology Research at ASCO 2015 #

Bayer HealthCare announced today that several studies on its latest oncology research will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2, in Chicago, Illinois (USA).   » more

2015-05-04
Bayer Licenses ISIS-FXI Rx from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis

Bayer Licenses ISIS-FXI Rx from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis #

Bayer HealthCare (Bayer) has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) on ISIS-FXIRx, an antisense drug in clinical development for the prevention of thrombosis.   » more

2015-05-04
Bayer’s Xarelto® Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis

Bayer’s Xarelto® Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis #

Bayer’s once-daily oral anticoagulant Xarelto® (rivaroxaban) has been approved by the China Food and Drug Administration (CFDA) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.   » more

2015-04-30

Strong start to the year for Bayer

The Bayer Group had a strong start to 2015 and once again expanded sales in the first quarter. "At HealthCare we continued to benefit from the positive development of our recently launched pharmaceutical products and the gratifying expansion of business in Consumer Health," Bayer CEO Dr. Marijn Dekkers said on Thursday when the interim report was published.   » more

2015-04-24
Bayer Submits Marketing Authorization for Radium-223 Dichloride to Treat Prostate Cancer with Bone Metastases in Japan

Bayer Submits Marketing Authorization for Radium-223 Dichloride to Treat Prostate Cancer with Bone Metastases in Japan #

Bayer HealthCare has submitted an application for marketing authorization to the Ministry of Health, Labour and Welfare (MHLW) in Japan for radium-223 dichloride (radium-223) solution for injection for the treatment of prostate cancer patients with bone metastases.   » more

2015-04-23
Bayer supports cancer biomarker research in Europe

Bayer supports cancer biomarker research in Europe

Bayer HealthCare and University Medical Center Hamburg-Eppendorf (UKE) are the main coordinators of the newly founded international consortium CANCER-ID to develop and validate novel blood-based biomarker technologies in cancer.   » more

2015-04-15

Bayer to Present New Data on Advancing Oncology Portfolio #

Bayer HealthCare (Bayer) will present latest preclinical and clinical data on oncolocgy compounds with new mechanism of action including several potent and selective small molecule inhibitors and an antibody-drug conjugate at the American Association for Cancer Research (AACR) 106th Annual Meeting, April 18-22, 2015, in Philadelphia, PA.   » more

2015-04-14
Bayer Expands Clinical Development Program for Novel PI3K Inhibitor Copanlisib in Non-Hodgkin’s Lymphoma

Bayer Expands Clinical Development Program for Novel PI3K Inhibitor Copanlisib in Non-Hodgkin’s Lymphoma #

Copanlisib is a novel intravenous pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against both PI3K-? and PI3K-? isoforms. The PI3K pathway is one of the most frequently altered pathways in cancer and the PI3K isoforms regulate many cellular functions, such as growth control, metabolism and transcription initiation.   » more

2015-04-13
Bayer’s Companion Vector-Borne Diseases Web Conference Advances “One Health” Approach

Bayer’s Companion Vector-Borne Diseases Web Conference Advances “One Health” Approach

Nearly half of the world’s population is infected with at least one type of vector-borne disease(i). These diseases are transmitted from parasites to animals and humans, and have a significant impact on public health and the global economy.   » more

2015-04-01
New Phase 3 Study in China Confirms Vision Improvement for Patients with Wet Age-Related Macular Degeneration when Receiving Aflibercept Solution for Intravitreal Injection

New Phase 3 Study in China Confirms Vision Improvement for Patients with Wet Age-Related Macular Degeneration when Receiving Aflibercept Solution for Intravitreal Injection #

In the study of neovascular wet age-related macular degeneration (wet AMD) in China, patients receiving aflibercept solution for intravitreal injection 2 milligrams (mg) achieved superiority in visual and anatomical endpoints compared to photodynamic therapy.   » more

2015-03-31
Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease

Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease

Cardiovascular genomics is an emerging field of cardiology that uses genomic information to characterize disease risk and identify new therapeutic targets for drug discovery.   » more

2015-03-26
Bayer receives approval for Gadovist® (gadobutrol) injection in Japan

Bayer receives approval for Gadovist® (gadobutrol) injection in Japan #

Bayer HealthCare received approval in Japan for Gadovist® (gadobutrol) injection for use with magnetic resonance imaging (MRI). Gadovist is the first high concentration/high relaxivity gadolinium-based contrast agent to be approved in Japan and is indicated for contrast-enhancement MRI in cranial, spinal, the body and extremeties at a dose of 0.1 mL/kg body weight. In Japan, there are more than 1.6 million MRI procedures conducted annually which are contrast-enhanced.   » more

2015-03-24

Bayer to present new preclinical, early clinical and epidemiological data on advancing portfolio in gynecological therapies #

Bayer HealthCare (Bayer) will present latest preclinical, early clinical and epidemiological data on its advancing gynecological therapies portfolio at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA.   » more

2015-03-23
Bayer Furthers Global Efforts to Lead Fight Against Vector-Borne Diseases

Bayer Furthers Global Efforts to Lead Fight Against Vector-Borne Diseases

In its 10th year, the Companion Vector-Borne Diseases (CVBD®) World Forum leads a global public health conversation on vector-borne diseases under the banner: “One Health: joining efforts for a healthier world”.   » more

2015-03-11

Bayer to Present Latest Clinical Data in the Area of Kidney Diseases #

Bayer HealthCare will present latest clinical data on development candidates in the area of kidney diseases at the World Congress of Nephrology (WCN), March 13-17, 2015, in Cape Town, South Africa. An oral and poster presentation will describe the results from the Phase IIb ARTS-DN study with finerenone for the treatment of patients with diabetic nephropathy.   » more

2015-03-11
Bayer Submits Aflibercept Solution for Intravitreal Injection for the Treatment of Myopic Choroidal Neovascularization in the EU

Bayer Submits Aflibercept Solution for Intravitreal Injection for the Treatment of Myopic Choroidal Neovascularization in the EU #

Bayer HealthCare has submitted an application for marketing authorization of aflibercept solution for intravitreal injection for the treatment of myopic choroidal neovascularization (myopic CNV) to the European Medicines Agency (EMA).   » more

2015-03-05

Phase III Trial of Regorafenib Shows Insufficient Patient Recruitment #

Bayer HealthCare today announced that it is suspending enrolment into a Phase III trial with regorafenib (Stivarga®) in colorectal cancer patients with resected liver metastases due to insufficient patient recruitment.   » more

You see the news 1 to 30 out of 365
1 2 3 4 5 6 7 8 9 10 Next >
Bayer HealthCare Links

RSS Feed
RSS Feed

http://press.healthcare.bayer.com/en/press/news/news-archive/index.php

Copyright © Bayer HealthCare AG